acquired
Stage
2009
Founded
2
Investors
About
Covagen AG was a biopharmaceutical company that developed multispecific FynomAb® biologics for the treatment of inflammatory diseases and cancer. The company was acquired by Cilag GmbH International, a Johnson & Johnson company, in 2014.
Explore Covagen's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.